Claude Nicaise is Director at Sarepta Therapeutics, Inc. (SRPT). They have made 1 open-market trade across 1 company since 2025, most recently 2026-06-04.
CIK 0001644162
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SRPT | 48,407 | $828K |
Shares reported on the most recent Form 4, priced at the 2026-06-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SRPT | SELL | 2025-03-12 | 2025-03-13 | $99.64 | $496K | -25.6% | -44.8% | -61.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.